Uncontrolled Asthma: Changing the Treatment Paradigm for Managed Care Populations
Webinar Recorded on August 6, 2020
Sponsored by GSK
Asthma remains a serious health risk in the US, with, according to the American Lung Association, 3,518 deaths, 188,965 hospitalizations, and 1.7 million emergency department visits. Having uncontrolled versus controlled asthma, significantly increases these unscheduled visits, as well as being associated with higher healthcare costs.
Approximately 30% of patients adherent to ICS/LABA remain uncontrolled. For these patients, factors to consider in your treatment protocols include:
- The goals of asthma management, which include symptom control and risk management
- Incorporating use of asthma assessment tools and measures to assists in determining best overall treatment and medication pathways
- Recommendations from the asthma guidelines
This program reviews the recommended tools for assessment and management, as well as pharmacotherapy considerations to improve risk management and control. A case study outlining the recommendations provides practical considerations to help managed care professionals better understand the complexity of uncontrolled asthma and ensure appropriate access using these evidence-based approaches.
- Anne Marie Ditto, MD, FAAAAI, FACAAI, FISAAI
US Medical Expert, Respiratory, GSK, Medical Affairs
Asthma Clinic Attending, Community Health, Chicago
Former Associate Professor of Medicine, Division of Allergy-Immunology, Northwestern University Feinberg School of Medicine
This webinar is sponsored, developed and presented by the sponsor. The content of this Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.